Concepedia

Adam Giermasz

AG

Statistics

Publications

38

Citations

2K

H-Index

22

Active since

1995

Affiliations

Medical University of Warsaw(Current)

University of California, Davis

Pfizer (United States)

University of California, San Francisco

University of Michigan

Adam Giermasz is an author at Medical University of Warsaw specializing in medicine, gene therapy, and oncology.

Publications per year

1995–2025

38

Publications

38

Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant

Lindsey A. George, Spencer K. Sullivan, Adam Giermasz et al. · New England Journal of Medicine · 2017 · 759 citations · Full text

Medicine, Hematology, Molecular Medicine +15

Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B

Annette von Drygalski, Adam Giermasz, Giancarlo Castaman et al. · Blood Advances · 2019 · 135 citations · Full text

Medicine, Hematology, Pharmacotherapy +12

Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice.

Wojciech Feleszko, Ewa Bałkowiec-Iskra, Anna Czajka et al. · PubMed · 2000 · 134 citations

Medicine, Oncology, Pharmacology +15

Lovastatin and tumor necrosis factor-? exhibit potentiated antitumor effects against Ha-ras-transformed murine tumorVia inhibition of tumor-induced angiogenesis

Wojciech Feleszko, Ewa Z. Ba kowiec, Elisabeth Sieberth et al. · International Journal of Cancer · 1999 · 93 citations

Medicine, Oncology, Pharmacology +11

Activity of transgene-produced B-domain–deleted factor VIII in human plasma following AAV5 gene therapy

S. Rosén, Stefan Tiefenbacher, Mary Robinson et al. · Blood · 2020 · 71 citations · Full text

Life Sciences, Genetics, Molecular Biology +13

1–5 of 38